ArticleEndocrine oncology (Bristol, England)2025
Real-world outcomes of lower lenvatinib doses in advanced neuroendocrine tumors: a multinational retrospective study.
Article in Endocrine oncology (Bristol, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Renal Cell Carcinoma in the Geriatric Population: Toward a Frailty-Adapted Therapeutic Paradigm.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Neuroendocrine tumors (NET) are heterogeneous neoplasms with increasing incidence and limited treatment options for advanced, progressive disease. Lenvatinib, a multitargeted TKI, demonstrated high efficacy but substantial toxicity at the standard 24 mg/day in the phase II TALENT trial. This study evaluates real-world efficacy and safety of lower-dose lenvatinib in patients with grade 1-3 GEP or thoracic NET. Design: Retrospective multinational cohort study. Methods: Twenty-two patients from Brazil, Argentina, and Israel with grade 1-3 NET and radiologic progression received lenvatinib (starting doses per physician discretion) between March 2021 and September 2024. The primary endpoint was progression-free survival (PFS); secondary endpoints were overall survival (OS) and grade ≥3 adverse events (AEs). Exploratory endpoints included objective response rate (ORR) and disease control rate (DCR). Kaplan-Meier methods estimated time-to-event outcomes; AEs were graded per CTCAE v5.0. Results: Median age was 60 years (range: 36-81); primary sites were pancreatic (27%), gastrointestinal (54.5%), and thoracic (18.2%). Grades: G1 (23%), G2 (45%), G3 (31.8%). Starting doses ranged 8-24 mg/day, most often 10 mg (32%) or 8 mg (27%); 45% required reductions. Mean daily dose was 11.8 mg (±4.7). After 16.8 months median follow-up, mPFS was 13 months (IQR: 8.8-17.9) and mOS 16 months (IQR: 12.6-18.5). Among 22 evaluable patients, ORR was 31.8% and DCR 90.9%. Grade 3-4 AEs occurred in 22%; most were grade 1-2 (fatigue 31.8%, hypertension 22.7%). Conclusions: Lenvatinib (average of 10-12 mg/day) showed meaningful antitumor activity and improved tolerability in advanced GEP and thoracic NET, supporting individualized dosing to enhance safety without compromising efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.